Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Invested Capital (2016 - 2025)

Historic Invested Capital for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $161.5 million.

  • Regenxbio's Invested Capital fell 4643.55% to $161.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.5 million, marking a year-over-year decrease of 4643.55%. This contributed to the annual value of $259.7 million for FY2024, which is 1670.97% down from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Invested Capital is $161.5 million, which was down 4643.55% from $213.7 million recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's Invested Capital peaked at $764.3 million during Q4 2021, and registered a low of $161.5 million during Q3 2025.
  • For the 5-year period, Regenxbio's Invested Capital averaged around $430.7 million, with its median value being $405.9 million (2023).
  • As far as peak fluctuations go, Regenxbio's Invested Capital skyrocketed by 10232.74% in 2021, and later tumbled by 4643.55% in 2025.
  • Over the past 5 years, Regenxbio's Invested Capital (Quarter) stood at $764.3 million in 2021, then tumbled by 32.46% to $516.2 million in 2022, then tumbled by 39.61% to $311.7 million in 2023, then dropped by 16.71% to $259.7 million in 2024, then tumbled by 37.82% to $161.5 million in 2025.
  • Its Invested Capital was $161.5 million in Q3 2025, compared to $213.7 million in Q2 2025 and $274.2 million in Q1 2025.